Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Oral ELND005 (scyllo-inositol) for Agitation and Aggression in Moderate to Severe Alzheimer's Disease
2012-004299-20Phase 2Completed
- Sponsor
- Transition Therapeutics Inc.
- Start
- Feb 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing ELND005 arm with Placebo arm (2 arms). Primary endpoint: Primary efficacy endpoint. Started Feb 2013; status: completed.
02
Drugs
scyllo-inositol
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2012-004299-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004299-20.